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Abstract
Background: The Retinoblastoma protein (pRB) is a key tumor suppressor that is functionally inactivated in most
cancers. pRB regulates the cell division cycle and cell cycle exit through protein–protein interactions mediated by its
multiple binding interfaces. The LXCXE binding cleft region of pRB mediates interactions with cellular proteins that
have chromatin regulatory functions. Chromatin regulation mediated by pRB is required for a stress responsive cell
cycle arrest, including oncogene induced senescence. The in vivo role of chromatin regulation by pRB during
senescence, and its relevance to cancer is not clear.
Methodology/Principal Findings: Using gene-targeted mice, uniquely defective for pRB mediated chromatin
regulation, we investigated its role during transformation and tumor progression in response to activation of
oncogenic ras. We report that the pRB∆L mutation confers susceptibility to escape from HrasV12 induced senescence
and allows transformation in vitro, although these cells possess high levels of DNA damage. Intriguingly, LSL-Kras,
Rb1∆L/∆L mice show delayed lung tumor formation compared to controls. This is likely due to the increased apoptosis
seen in the early hyperplastic lesions shortly following ras activation that inhibits tumor progression. Furthermore,
DMBA treatment to induce sporadic ras mutations in other tissues also failed to reveal greater susceptibility to cancer
in Rb1∆L/∆L mice.
Conclusions/Significance: Our data suggests that chromatin regulation by pRB can function to limit proliferation,
but its loss fails to contribute to cancer susceptibility in ras driven tumor models because of elevated levels of DNA
damage and apoptosis.
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Introduction

inhibiting or delaying tumor progression in response to
oncogene activation in vivo.
Senescence is associated with activation of tumor
suppressor pathways regulated by p53 and pRB proteins [5,6].
These two pathways coordinately inhibit the growth of precancerous cells and prevent them from becoming tumors.
Accordingly, disruption of these tumor suppressor pathways
has been shown to result in increased susceptibility to
tumorigenesis in response to oncogenes [4,7–10]. In mouse
models, simultaneous activation of oncogenes such as
HrasG12V or BRAFV600E combined with loss of p53 or p16,
that act upstream of pRB, resulted in escape for OIS and
malignant transformation [7–9]. Notably, enhanced tumor
progression in these models strongly correlates with loss of
oncogene induced senescence markers, further supporting the

Oncogene induced senescence (OIS) has emerged as a
tumor suppressive mechanism that acts as a barrier to
transformation in vivo [1]. Pre-malignant lesions such as
melanocytic nevi and prostatic intraepithelial neoplasias (PIN
lesions) in humans are found to be rich in cells expressing
markers of senescence, while senescent cells are rarely found
in the corresponding malignant stages [2–4]. In recent years,
mouse models of human cancer have been generated that
show activation of senescence in response to the expression of
oncogenes [2]. Similar to human lesions, senescence in these
mouse models is predominantly associated with pre-malignant
stages of tumorigenesis suggesting a role for senescence in
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lack of pRB is knoen to promote malignant transformation and
enhance tumorigenesis [25]. However, the contribution of
different aspects of pRB function to its tumor suppressive role
is not clear as complete deletion of the Rb1 gene has many
consequences.
In order to investigate the role of chromatin regulation by
pRB during oncogene induced senescence and tumorigenesis
in vivo, we used a gene targeted mouse model in which the
endogenous Rb1 allele is mutated to encode a protein that is
defective in binding to chromatin regulators [26]. This allowed
us to study the role of chromatin regulation by pRB in isolation,
as the pRB∆L mutant is able to interact with and regulate E2F
transcription factors similarly to wild type. In order to investigate
what affect the Rb1∆L mutation might have on tumor
susceptibility in vivo, in response to activated oncogenes, we
crossed Rb1∆L/∆L mice with LSL-KrasG12D mice. We show that
the Rb1∆L mutation allows escape for OIS and immortalization
in vitro. However, these cells sustain extensive DNA damage.
Surprisingly, the Rb1∆L mutation delays lung tumors in the LSLKrasG12D mice. LSL-Kras; Rb1∆L/∆L compound mutant mice
show fewer lung adenomas compared to LSL-KrasG12D mice
alone following adenovirus-cre mediated activation of
oncogenic Kras in the lung. Increased apoptosis in early stage,
atypical hyperplastic lesions, correlates with reduced
adenomas later during tumor development. We further show
that chromatin regulation by pRB does not accelerate
tumorigenesis in a chemical carcinogen model that is known to
induce ras mutations. Taken together, our results suggest that
loss of chromatin regulation by pRB facilitates escape from cell
cycle arrest, but elevated levels of DNA damage and apoptosis
prevent it from synergizing with oncogenic ras.

notion that escape from OIS is a prerequisite for malignant
progression.
Senescence is a permanent cell cycle exit in which cells can
remain in a state of arrest throughout the life span of the
organism [5]. The permanence of a senescent arrest is partly
attributed to the chromatin changes that repress transcription,
and block DNA synthesis and cell division [11]. Senescent cells
form heterochromatin bodies called senescence associated
heterochromatic foci (SAHFs) that are proposed to encompass
and silence proliferative genes [12]. SAHFs are enriched in
repressive chromatin modifications such as H3K9me3 and
H3K27me3 and several chromatin associated proteins that aid
in chromatin compaction and transcriptional repression [12,13].
Defects in this heterochromatin assembly pathway have been
shown to compromise the stability of a senescent arrest in vitro
and are predicted to promote tumorigenesis in vivo [10].
Intriguingly, mice lacking Suv39h1, the enzyme capable of trimethylating histone H3K9, show defective senescence in
response to oncogenic stress and display increased
susceptibility to tumorigenesis in the Eµ-Nras model that
expresses oncogenic NrasG12D in the hematopoietic
compartment [10]. However, whether or not the chromatin
changes during senescence have a broader tumor suppressive
role in vivo, in response to oncogene activation in different
tissues is still an open question that needs further investigation.
Lung cancer is the leading cause of cancer related deaths in
humans and the most common type of lung cancer is the
pulmonary adenocarcinoma [14,15]. Activated K-Ras mutations
are the most frequent genetic alteration and they are
associated with approximately 30% of human lung
adenocarcinomas [15,16]. Over the last two decades a number
of mouse strains have been generated to model human lung
adenocarcinomas and they have greatly aided our
understanding of the progression of the disease, as well as the
oncogenes and tumor suppressors that influence it [17].
Conditional mutant models were generated harboring a latent
mutant allele of KRas (LSL-KrasG12D) at its endogenous locus
that can be activated sporadically in the lung cells by
administering a cre expressing adenovirus [18–20]. This model
closely mimics the human disease and allows for investigation
of the different stages of lung cancer progression.
The pRB tumor suppressor pathway is disabled in most
human cancers [21]. Although mutations of RB1 are rare in
lung adenocarcinomas, CDKN2A, the gene encoding p16INK4a
the upstream activator of the pRB pathway is a frequently
targeted for mutation [22]. p16INK4a is a cyclin dependent kinase
inhibitor (CKI) that inhibits D type cyclins associated with Cdk4
or Cdk6 in the G1 phase of the cell cycle, resulting in hypophosphorylation and activation of pRB in response to
oncogenic insults. The pRB tumor suppressor protein acts by
repressing E2F dependent transcription of genes involved in
cell cycle progression both by direct binding and also through
recruitment of chromatin regulatory complexes to these
promoters [23]. pRB is one of the major effectors of
senescence and both E2F inhibition and chromatin regulatory
functions have been shown to be crucial for proper senescent
arrest in cultured cells in response to activated oncogenes
[11,12,24]. In the LSL-KrasG12D lung cancer model, complete
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Results
The Rb1∆L mutation promotes escape from OIS and
transformation in vitro
Using mouse embryonic fibroblasts (MEFs) we previously
reported that pRB-LXCXE binding cleft mediated interactions
are required for heterochromatin assembly and stable
repression of E2F target genes during senescence [24]. In
response to oncogenic Hrasv12 expression, Rb1∆L/∆L MEFs
undergo a defective senescence arrest that is characterized by
elevated DNA synthesis and sensitivity to cell cycle re-entry in
response to stimuli such as ectopic E2F1 expression. We
wondered if the Rb1∆L mutation allows senescent Rb1∆L/∆L
MEFs to escape permanently from oncogenic HrasV12 induced
senescent arrest and immortalize. In order to test this, we
induced senescence in asynchronously growing wild type and
Rb1∆L/∆L MEFs by expressing oncogenic HrasV12 by retroviral
transduction. HrasV12 expressing cells were selected for 3
days in puromycin containing medium following which they
were re-plated at low density and cultured further in selection
medium until they become senescent. 10 days after re-plating,
most cells in both genotypes were senescent as determined by
senescence associated β-galactosidase (SA-β-gal) staining
and BrdU incorporation (Figure 1A). We then continued to
culture the cells in puromycin containing medium to monitor
spontaneous escape from senescence arrest. We quantified
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these clones attain anchorage independent growth potential in
soft agar, suggestive of transformation.

the number of spontaneous escape events by counting the
distinct foci that appeared in these cultures. We counted a
significantly higher number of foci in Rb1∆L/∆L cultures compared
to the wild type cultures 3 weeks following HrasV12 expression
(Figure 1B). The cells in these foci had lost the characteristic
features of senescence, such as flattened morphology,
vacuolated cytoplasm, and enlarged nuclei (data not shown).
Interestingly, the foci in Rb1∆L/∆L cultures were bigger and often
formed multilayered aggregates suggestive of loss of contact
inhibition, characteristic of immortalized cell clones (Figure 1C).
This suggests that the Rb1∆L mutation increases susceptibility
to escape from oncogene induced senescence (OIS) and this
might lead to spontaneous immortalization in culture.
In order to determine if these foci are composed of
immortalized cells that have permanently escaped from
senescence, and to study their growth characteristics, we
isolated cells from foci from both the Rb1+/+ and Rb1∆L/∆L
cultures expressing HRasV12. We sub-cultured the cells
extracted from the foci in puromycin containing medium and
analyzed them for proliferation and senescence using BrdU
labeling and SA-β-gal staining respectively. Interestingly, most
of the clones recovered from Rb1+/+ cultures failed to survive
the sub-culturing process and all of them eventually arrested
with features of senescence (Figure 1D). In contrast, we were
able to successfully sub-culture about half the clones
generated from Rb1∆L/∆L cultures. However, these clones
showed varied growth properties prompting us to categorize
them into slow growing and fast growing groups (Figure 1D).
The slow growing clones still showed significantly higher BrdU
incorporation compared to the cells from Rb1+/+ clones (Figure
1D). Strikingly, the fast growing clones had a very high
proportion of BrdU positive cells and very few cells stained
positive for SA-β-gal. These cells showed a highly refractive
spindle shaped appearance and had an increased metabolic
rate as suggested by rapid acidification of culture medium (data
not shown). This suggests that the Rb1∆L/∆L MEFs that escape
from oncogenic HrasV12 induced senescent arrest have
increased proliferative capability and show characteristic
properties of immortalized cell clones.
We next performed soft agar colony formation assays to
determine if the escaped clones are capable of anchorage
independent growth, indicative of transformation in vitro (Figure
1E). We used 293-T cells as a positive control for our assay.
After two weeks of culturing, most cells from the Rb1+/+ clone
failed to grow in soft agar. In contrast, cells from the fast
growing Rb1∆L/∆L clones formed multicellular aggregates
suggesting that they are capable of anchorage independent
growth. Interestingly, although some of the cells from the slow
growing Rb1∆L/∆L clones managed to form small aggregates in
soft agar, we noticed cell death in these aggregates that seem
to limit further growth. This suggested that in contrast to the
Rb1+/+ clones, Rb1∆L/∆L clones that had escaped from
senescence were capable of anchorage independent growth.
However, cell death likely limits the in vitro transformation
potential of some of these immortalized clones.
Taken together, the experiments above suggest that the
Rb1∆L mutation promotes escape from oncogenic HrasV12
induced senescence and immortalization in vitro. Some of
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The p53-p21 pathway limits the growth potential of
escaped Rb1∆L/∆L cell clones expressing HrasG12V
We wanted to further investigate the molecular basis of
differential growth properties and in vitro transformation abilities
of the sub-cultured foci that had escaped senescence and
determine which other pathways might be limiting the
transforming ability of these clones. Oncogenic ras has been
shown to induce hyper proliferation and replication stress
resulting in increased DNA damage [27–29]. Elevated DNA
damage response (DDR) signaling results in the
phosphorylation and activation of the p53 tumor suppressor
protein. Loss of pRB function has previously been shown to
result in p53 activation mediated by E2F1 and p19ARF leading to
increased apoptosis in response to oncogenic ras [30]. Given
that the Rb1∆L mutation leads to deregulated E2F target gene
expression during senescence [24], we wondered if the p53
pathway could act as a checkpoint to limit transformation of
Rb1∆L/∆L cells expressing Hras.
We first analyzed whether DNA damage signaling is intact in
Rb1+/+ and Rb1∆L/∆L sub-cloned foci (Figure 2A and B). Escaped
clones from both the Rb1+/+ and Rb1∆L/∆L senescent cultures
showed high levels of DNA damage as shown by the increased
quantity of γH2AX foci/nucleus (Figure 2A). Strikingly, the fast
growing clones have significantly higher levels of foci/cell (>10)
compared to both the slow growing Rb1∆L/∆L and the Rb1+/+
clones. Moreover, cells in the Rb1∆L/∆L clones, where γH2AX
stained the entire nucleus, were suggestive of drastic DNA
damage. We also analyzed γH2AX abundance by western
blotting. As shown in Figure 2B we were able to detect γH2AX
in senescent cells as well as all five sub-cultured clones that
we tested. Interestingly, senescent Rb1∆L/∆L MEFs showed
higher γH2AX levels and p21 induction compared to wild type
cells, suggesting that the Rb1∆L mutation confers susceptibility
to DNA damage and this results in increased activation of the
p53-p21 pathway during the initial senescent arrest. Similar to
immunofluorescent microscopy in Figure 2A, the fast growing
Rb1∆L/∆L clones showed relatively higher levels of γH2AX
compared to the slower growing clones by western blotting
(Figure 2B). Furthermore, all clones showed similar expression
of ras by western blotting. We wondered if the increased DNA
damage results in the activation of the p53-p21 pathway in
these clones. As shown in Figure 2B, we could detect
phosphorylation of p53 at ser15 in slow growing sub-cultured
clones and we interpret p53 to be active in these cells because
we also detect p21 expression. Interestingly, in the fast growing
Rb1∆L/∆L clones p53 is incapable of inducing the expression of
p21 despite high levels of phosphorylation of p53 at ser-15.
This indicates that p53 is functionally inactive in fast growing
cells that have escaped a senescent arrest.
Oncogenic ras expression induces the expression of PML
and assembly of PML nuclear bodies that are important for
growth suppression in a p53 dependent manner [31,32]. PML
has been shown to have an essential role during apoptosis and
cooperates with p53 to induce apoptosis in response to DNA
damage [30,33]. Consequently, we investigated the PML
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Figure 1. Escape from HrasV12 induced senescence and transformation in Rb1∆L/∆L MEFs. Asynchronously growing wild type
and Rb1∆L/∆L MEFs are induced to senesce by retroviral mediated expression of oncogenic HrasV12. After 3 days of selection, cells
were plated in medium and cultured for at least 10 days. All cells were pulse labeled with BrdU for 4 hours. (A) The percentage of
BrdU and SA β-gal positive cells in senescent Rb1+/+ and Rb1∆L/∆L cultures were determined. (B) Quantitation of foci from senescent
Rb1+/+ and Rb1∆L/∆L cultures. The average number of foci formed 3 weeks post selection were compared between genotypes. The
mean number of foci was compared between genotypes using a t-test (* p<0.0004). (C) Phase contrast microscopy images of wild
type and Rb1∆L/∆L cells either senescent (10 days post-selection) or foci (3 weeks post-selection). (D) The percentage of BrdU and
SA β-gal positive cells in sub-cultured foci from senescent Rb1+/+ and Rb1∆L/∆L cells was determined. Rb1∆L/∆L clones were grouped
into slow growing (slow) or fast growing (fast) based on their proliferative capacity as determined by BrdU incorporation and SA βgal staining. Mean values were compared with wild type controls using a t-test (* p<0.05). (E) Sub-cultured foci were also subjected
to culture in soft agar to determine their capacity for anchorage independent growth. 293-T cells were used as a positive control.
Quantitation after 2 weeks of culturing in soft agar is shown on the right. The average number of colonies/field was determined from
10 random fields and mean colony values were compared with wild type using a t-test. (* p<0.05).
doi: 10.1371/journal.pone.0072236.g001
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Figure 2. Increased DNA damage in Rb1∆L/∆L cells sub-cultured from foci. Rb1+/+and Rb1∆L/∆L clones were sub-cultured from
foci and stained with antibodies against γH2AX and PML. (A) Immuno-fluorescent staining of Rb1+/+ and Rb1∆L/∆L clones with a
γH2AX specific antibody to determine the extent of DNA damage. Quantitation is shown in the graph on the right. Asterisk indicates
significant difference from wild type controls (t-test, p<0.05). Scale bars are 10µM. (B) Western blots for DNA damage response
proteins in senescent Rb1+/+ and Rb1∆L/∆L MEFs (left) and slow and fast growing Rb1∆L/∆L sub-cultured foci are shown. (C) Anti-PML
antibody staining of Rb1+/+ and Rb1∆L/∆L cells sub-cultured from foci. Quantitation of PML nuclear bodies is shown on the graph to the
right. Asterisk indicates significant difference from wild type controls (t-test, p<0.05). Scale bars are 10µM.
doi: 10.1371/journal.pone.0072236.g002
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period, as well as progression at 6, 8, 10, 12, and 16 week time
points.
Deletion of pRB has been previously shown to co-operate
with oncogenic KrasG12D to promote tumorigenesis in this
background [25]. These compound mutant mice develop more
aggressive tumors and succumb to their tumors earlier than
KrasG12D mice alone. We hypothesized that the Rb1∆L
mutation would permit escape from senescence in lung tumor
lesions, thus accelerating tumorigenesis. However, as shown in
Figure 3C the Rb1∆L mutation did not significantly alter the
tumor free survival of the oncogenic KrasG12D expressing
mice. The median survival was 163.5 days following activation
of oncogenic KrasG12D by Ad-Cre for the LSL-Kras, Rb1+/+
mice compared to 183 days for the compound mutant LSLKras, Rb1∆L/∆L mice (Figure 3C). This suggested that, in
contrast to our in vitro results where Rb1∆L promotes escape
from oncogene induced senescence and transformation, the
Rb1∆L mutation does not promote tumorigenesis or affect the
tumor free survival of mice expressing oncogenic ras in vivo.

nuclear body formation in the escaped clones. All of the clones
tested displayed abundant PML bodies in the nucleus that were
similar in quantity to senescent cells. This suggests that the
pathway upstream of PML body formation is still intact and the
escape from senescence is due to defects downstream of PML
body formation (Figure 2C).
These experiments show that the initial signaling events in
response to the expression of oncogenic ras are still active in
the cell clones that escape from senescence. The escaped
clones accumulate DNA damage resulting in the activation of
the p53-p21 pathway. In vitro transformation and anchorage
independent growth in soft agar correlates with disruption of
the p53-p21 pathway. Taken together, this indicates that
defective senescence in Rb1∆L/∆L cells allows resumption of
proliferation, but this is opposed by p53.

The Rb1∆L mutation does not enhance oncogenic ras
driven cancer
We used 7,12-dimethyl benz[a]anthracine (DMBA) induced
chemical carcinogenesis to induce tumors. Administration of
DMBA has been shown to cause ras mutations and promote
tumorigenesis in several tissues in mouse models of cancer
[34,35]. We wanted to investigate if the Rb1∆L mutation
promotes tumorigenesis in response to DMBA treatment. We
treated six week old Rb1+/+ and Rb1∆L/∆L mice with DMBA once
a week for four weeks by oral gavage and monitored the mice
for tumors. As seen in Figure 3A, the Rb1∆L mutation did not
significantly alter the tumor free survival of the mice in a DMBA
induced tumor model. The overall tumor free survival rate was
similar between the genotypes with 95% of Rb1+/+ mice and
100% Rb1∆L/∆L mice succumbing to tumors. The median tumor
free survival is 320.5 days for the Rb1∆L/∆L mice compared to
299 days for the Rb1+/+ mice (p=0.0537, log rank test),
indicating that Rb1∆L/∆L mice may actually be slightly resistant
even though this difference doesn’t reach a 95% confidence
interval. Necropsies of the mice from both groups revealed
tumor burden in a broad range of tissues (Figure 3B). In
addition, we did not observe a significant difference between
the two groups in terms of disease site as both genotypes
developed a broad range of cancer types. Given the
preponderance of ras mutations that are known to be caused
by DMBA, it suggests that the Rb1∆L mutation does not
promote tumorigenesis in response to oncogenic ras.
To follow up on this surprising result, we switched to a well
characterized oncogenic Kras induced lung cancer model, LoxSTOP-Lox-KrasG12D (henceforth referred to as LSL-Kras)
[18,20]. In this system we can control the initiation of cancer
through adenovirus cre (Ad-Cre) administration, and
investigate progression to determine the effects of the Rb1∆L
mutation on oncogenic ras driven cancer. We crossed LSLKras mice with Rb1∆L/∆L mice that are defective for LXCXE
binding cleft mediated interactions to generate compound
mutant mice (LSL-Kras, Rb1∆L/∆L). We then induced the
expression of the latent Kras allele in both the control mice
(LSL-Kras, Rb1+/+) and our compound mutant mice using AdCre by intranasal infection. We monitored the mice following
Ad-Cre infection for lung tumor free survival over a 40 week
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Fewer lung tumor lesions in Rb1∆L/∆L mice expressing
oncogenic Kras
Oncogene induced senescence is widely believed to act as a
barrier to transformation and cancerous growth in vivo, and
expression of oncogenic ras has been shown to activate
senescence thereby limiting tumorigenesis in mouse models
[2]. Our in vitro results suggested that cells from Rb1∆L/∆L mice
have defective senescence allowing them to escape from this
arrest and transform. However, this did not lead to enhanced
tumor susceptibility in vivo, as a result we wanted to further
investigate tumorigenesis in the LSL-Kras, Rb1∆L/∆L mice more
closely by quantifying the number of lesions that develop in
response to Kras activation.
We investigated lung tumor lesions from the LSL-Kras,
Rb1+/+ and LSL-Kras, Rb1∆L/∆L mice post activation of oncogenic
Kras by Ad-Cre. At 12 weeks post adenovirus infection, we
were able to detect the different types of lesions that define
progression in this model and many were visible at a gross
level (Figure 4A). Similar to previous reports in the literature
[18], we detected atypical adenomatous hyperplasia (AAH),
adenoma, adenocarcinoma, and epithelial hyperplasia of the
bronchioles (EHB) in both the experimental groups (Figure 4B–
E). AAH and adenoma are benign lesions and are considered
precursors for adenocarcinoma. As shown in Figure 4F, lungs
from LSL-Kras, Rb1∆L/∆L mice and LSL-Kras, Rb1+/+ controls
have similar levels of pre-malignant lesions at six weeks post
Ad-Cre treatment. Strikingly, by 12 weeks there were
significantly fewer adenomas in LSL-Kras, Rb1∆L/∆L mutants
(Figure 4G). One possibility for the reduced number of
adenomas seen in LSL-Kras, Rb1∆L/∆L mice at 12 weeks is
accelerated progression to adenocarcinoma. Since we did not
measure a concomitant increase in the number of
adenocarcinomas in LSL-Kras, Rb1∆L/∆L mice compared to
controls we think this explanation is unlikely. We also did not
detect any difference between the two groups in the number of
AAH lesions, the precursor of adenoma, at either time point.
Interestingly, at the time of harvesting the lungs for histology,
we routinely observed that the lungs from LSL-Kras, Rb1∆L/∆L
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Figure 3. The Rb1∆L mutation does not affect tumor free survival in multiple models of ras induced cancer. Six to eight
week old Rb1+/+ and Rb1∆L/∆L mice were dosed with 1mg of 7,12-dimethyl benz[a]anthracine (DMBA) in canola oil by orogastric
lavage weekly for 4 weeks. (A) Kaplan-Meier survival curves of Rb1+/+ (n=20) and Rb1∆L/∆L (n=20) mice treated with DMBA. The
median survival age is 299 for wild type and 320.5 days for Rb1∆L/∆L (p=0.0537, log rank test). (B) Quantification of tumor disease
sites at the time of necropsy in Rb1+/+ and Rb1∆L/∆L mice treated with DMBA. (C) Six to eight week old LSL-Kras, Rb1+/+ and LSLKras, Rb1∆L/∆L mice were infected intra-nasally with Ad-Cre to activate the oncogenic K-rasG12D allele. The mice were monitored
over time for tumor free survival. Kaplan-Meier survival curves LSL-Kras, Rb1+/+ (n=14) and LSL-Kras, Rb1∆L/∆L (n=14) mice. The
median survival age is 163.5 for control and 183 days for Rb1∆L/∆L (p=0.636, log rank test).
doi: 10.1371/journal.pone.0072236.g003
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Discussion

mice were smaller in size compared to the control LSL-Kras,
Rb1+/+ mice at 12 weeks (Figure 4A). Taken together, this
suggested that, tumor initiation levels were similar, but that the
Rb1∆L mutation ultimately impedes the growth of Kras induced
tumors.
In order to investigate the possible cause for the decreased
number of adenomas in LSL-Kras, Rb1∆L/∆L mice we first tested
the proliferation rate of the tumor cells between the two
genotypes at six weeks and 12 weeks following the activation
of Kras. We used Ki67 as a marker for proliferation and SA-βgal staining as a marker for senescence in the tumors. At both
time points tested, the proportion of Ki67 positive cells in the
adenomas is similar between the two experimental groups
(Figure 5A). This indicates that the tumor cells were
proliferating at similar rates in each genotype. Furthermore, we
also detected similar senescence staining in the AAH lesions
and in adenomas from LSL-Kras, Rb1+/+ and LSL-Kras, Rb1∆L/∆L
mice (Figure 5B). This further suggested that there is no defect
in the proliferation of tumor cells in LSL-Kras, Rb1∆L/∆L mice,
and activation of oncogenic Kras can initiate senescence in
these lesions similar to those in LSL-Kras, Rb1+/+ controls.

Our study shows that mutation of the LXCXE binding cleft
that disrupts chromatin regulation by pRb is sufficient for
escape
from
oncogene
induced
senescence
and
transformation in vitro. Interestingly, the pRB∆L mutation does
not promote tumorigenesis in vivo but instead, reduces
tumorigenesis in the KrasG12D lung cancer model by
negatively affecting early tumor progression.
We think there are a number of differences between our in
vitro and in vivo experiments that should be considered when
interpreting the results of this study. One is the obvious
differences in cell types between our experiments. Unlike the
lung alveolar pneumocytes, mouse embryonic fibroblasts
(MEFs) are not terminally differentiated cells. It is thus possible
that MEFs in culture are more readily immortalized whereas
additional checkpoints that prevent transformation of the
differentiated cells may exist in vivo. The increased apoptosis
we observe in the primary AAH lesions that are precursors of
adenomas and adenocarcinomas suggests this might be the
case. It is also interesting to note that MEFs do not undergo
apoptosis as robustly, and rather activate senescence in
response to persistent DNA damage [27,28,37]. Our data
indicates
that
defective
heterochromatinization
and
deregulation of cell cycle genes during senescence, as a result
of the Rb1∆L mutation, seems to be sufficient for random cells
to escape from this arrest and immortalize in vitro. However,
the relative contribution of apoptosis and senescence during
tumor suppression in vivo is not fully understood. Even though
both phenomenon are known to be tumor suppressive and are
regulated by the same tumor suppressor networks, how and at
what stage during tumor progression they coordinate to
suppress tumorigenesis remains unknown. We show that
senescence is activated in the lungs in response to the
activation of oncogenic Kras at a very early stage, and benign
lesions stain positive for SA β-gal, suggesting that senescence
does play a role in suppressing tumor progression in this
model. From this perspective it appears that oncogenic Kras
expression activates both apoptosis and the senescence
pathway. Based on our data, cell death by apoptosis and
senescence act in series to suppress the progression of benign
lesions into malignant adenocarcinomas.
The cause of the increased apoptosis we observed in the
LSL-Kras, Rb1∆L/∆L mice is not clear. A recent report has
suggested a complex interplay between heterochromatin
assembly during senescence and suppression of DNA damage
response (DDR) signaling [38]. The authors show that
disruption of heterochromatin in oncogene expressing cells
increases DDR signaling leading to apoptosis. Thus, it is
possible that defective heterochromatinization during
senescence as a result of the Rb1∆L mutation might be
exacerbating DDR signaling and induces apoptosis in these
lesions early during tumorigenesis. However defective
heterochromatinization in mice lacking Suv39h1, the enzyme
capable of tri-methylating histone H3K9, show increased
susceptibility to lymphoma development in an Eµ-Nras model
[10]. This suggests that regulation of heterochromatin by pRb is
not equivalent to H3K9 trimethylation and that heterochromatin

Increased apoptosis in atypical adenomatous
hyperplasia (AAH) lesions from Rb1∆L/∆L lungs
expressing oncogenic Kras
Oncogenic ras expression has been shown to induce
apoptosis through p53 or pRB-E2F1 pathways [36]. Our in vitro
results suggested that the clones that escaped senescence
have high levels of DNA damage as shown by increased
γH2AX staining and activation of the p53-p21 pathway. We
wondered if escape from senescence, as a result of the Rb1∆L
mutation, results in increased cell death by apoptosis in vivo.
This could potentially explain the reduced number of adenomas
that we observe in LSL-Kras, Rb1∆L/∆L mice.
We searched for evidence of apoptosis in the benign lung
lesions of both Rb1 genotypes. We performed TUNEL staining
on sections from LSL-Kras, Rb1+/+ and LSL-Kras, Rb1∆L/∆L mice
at different time points following K-rasG12D activation. We
noticed very few TUNEL positive cells in the adenomas from
the LSL-Kras, Rb1+/+ mice (Figure 5C) at 12 weeks post
activation of KrasG12D, suggesting absence of cell death in
these lesions. However, some of the adenomas from LSL-Kras,
Rb1∆L/∆L mice showed TUNEL positive cells at this time point
indicating cell death (Figure 5C). We hypothesized that
apoptosis might be activated early during tumor development in
response to activated ras and defective chromatin regulation by
pRB, and that this limits the progression of these lesions.
Therefore, we searched for apoptosis in lung sections of mice 6
weeks post activation of Kras by TUNEL staining. We counted
the TUNEL positive cells from at least 10 random fields from
each lung section and quantified how many of these are
associated with early hyperplastic lesions (i.e. AAH). We
observed a significantly higher number of TUNEL positive cells
that are associated with AAH lesions in the LSL-Kras, Rb1∆L/∆L
mice compared to the controls. This would result in fewer AAH
lesions progressing to the adenoma stage and explain why we
see lower numbers of adenomas in the LSL-Kras, Rb1∆L/∆L mice
compared to controls at 12 weeks post activation of KrasG12D.
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Figure 4. Fewer lung tumor lesions in Rb1∆L/∆L mice expressing KrasG12D. Six to eight week old LSL-Kras, Rb1+/+ and LSLKras, Rb1∆L/∆L mice were infected intra-nasally with Ad-Cre to activate the oncogenic KrasG12D allele. The mice were euthanized at
6 and 12 weeks post Ad-Cre infection. (A) Haematoxylin and Eosin stained lung sections from 12 week old mice of the indicated
genotypes are shown. Arrow heads indicate some of the lesions. Scale bars are 5 mm. (B) Microscopy images of H&E stained lung
tissues to demonstrate atypical adenomatous hyperplasia (AAH) in both LSL-Kras, Rb1+/+ and LSL-Kras, Rb1∆L/∆L mice. Scale bar is
50 µm. (C) H&E section of lung tissue to demonstrate adenomas in both genotypes of mice. Scale bar is 50 µm. (D) H&E section of
lung tissue showing adenocarcinoma tissue. Scale bar is 50 µm. (E) Lung tissue section showing H&E staining of epithelial
hyperplasia of the bronchioles (EHB). Scale bar is 50 µm. (F) Quantitation of the lung tumor lesion types in LSL-Kras; Rb1+/+ and
LSL-Kras; Rb1∆L/∆L mice at six weeks post Ad-Cre infection. Box and whisker plots show 25th percentile, median and 75th percentiles.
Whiskers show highest and lowest values in the group. Means were compared by t-test. (G) The same analysis as in A, except at
12 weeks post Ad-Cre infection. Means were compared by t-test, an asterisk indicates a statistically significant difference (p<0.05).
doi: 10.1371/journal.pone.0072236.g004
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Figure 5. Elevated apoptosis in atypical adenomatous hyperplasia lesions from lungs of Rb1∆L/∆L mice expressing
KrasG12D. Six to eight week old LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L mice were infected intra-nasally with Ad-Cre to activate
the oncogenic KrasG12D. Characteristics of lung tumors at six and 12 weeks post Ad-Cre infection were assessed. (A) Quantitation
of Ki67 positive cells in the adenomas from LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L lungs at the indicated time points. (B)
Senescence associated β-galactosidase staining of cryo-sections from LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L lungs at the
indicated time points. Sections were counterstained with haematoxylin. Scale bars are 50 µm. (C) Representative TUNEL stained
lung sections from LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L mice 12 weeks following Ad-Cre infection. DAPI was used to
counterstain the nuclei. Arrowheads indicate a selection of TUNEL positive nuclei. (D) Representative TUNEL stained lung sections
six weeks following Ad-Cre infection. DAPI was used to stain the nuclei. (E) Quantitation of TUNEL positive cells in B that are
associated with atypical adenomatous hyperplasia lesions in LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L lungs. Means were compared
by a t-test, statistically significant differences are shown by an asterisk (p=0.001). Scale bars are 50 µm.
doi: 10.1371/journal.pone.0072236.g005
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Ad-Cre infection

assembly can have context specific effects on cancer
progression.
Our studies using the LSL-Kras model and the DMBA
chemical carcinogenesis model show that the Rb1∆L mutation
does not promote tumorigenesis or affect overall survival of the
mice. Previous studies done using the Rb1∆L/∆L mice also
suggested a context specific role for the LXCXE binding cleft
during tumorigenesis [39,40]. The Rb1∆L mutation co-operates
with p53 loss to hasten tumor formation in mice [39]. The
tumors in the compound mutant mice are more genomically
unstable and the resulting tumors are also more aggressive.
Also, in a mammary tumorigenesis model, the Rb1∆L mutation
exacerbates the tumor phenotype in the Wap-p53 (R172H)
transgenic background. However, in the same study it was
found that the Rb1∆L mutation does not enhance mammary
tumors induced by the Neu oncogene. This suggests that
tumor suppression by the LXCXE binding cleft of pRb is highly
context specific. While the Rb1∆L mutation enhances
tumorigenesis when combined with p53 loss the same mutation
does not cooperate with oncogene activation in the receptor
tyrosine kinase (RTK)-ras pathway to promote tumor formation.
This might suggest that even though the Rb1∆L mutation results
in deregulated cell cycle gene expression and defective cycle
arrest, in vivo, the p53 pathway might act as an additional
barrier to suppress tumorigenesis. Increased apoptosis seen in
our LSL-Kras, Rb1∆L/∆L tumors also seems to support this
hypothesis. Tumor progression in these models might require
additional disruption of the p53 tumor suppressor pathway.
Future experiments using gene targeted mouse models with
subtle mutations like ours will help our understanding of the
complex relationship between different tumor suppressor and
oncogene networks that exist in vivo. Identification of
incompatibilities, as we have reported here, may offer new
therapeutic opportunities in the future.

Ad-Cre was administered by intranasal instillation as
described before [18,20]. We infected mice with 5x106
infectious particles of Ad-Cre in 75µl volume per mouse.

Histology
Lungs were fixed in formalin for 48hrs before embedding in
paraffin for staining with Haematoxylin and Eosin. For
immunohistochemistry, formalin fixed, paraffin embedded
tissues were deparrafinized in xylenes followed by rehydration
by serial washes in 100%, 95%, 70% ethanol. Antigen retrieval
was done by boiling the sections in a pressure cooker for
15min in 10mM sodium citrate buffer pH 6.0. TUNEL staining
was performed using in situ cell death detection kit from Roche
as per the manufacturers instructions (Cat. No. 11 684 795
910). Tissues for SA β-gal staining were fixed in optimum
cutting temperature (OCT) compound and embedded for cryosectioning.

Senescence β-galactosidase staining of tissues
Tissue sections were processed immediately after cryosectioning by fixing them in 0.5% glutaraldehyde/PBS for 15
minutes followed by O/N incubation in SA β-gal staining buffer
(40mM citric acid/sodium phosphate buffer at pH 6.0 containing
5mM potassium ferricyanide, 5mM potassium ferrocyanide,
2mM MgCl2 and 1mg/ml X-gal) at 37oC in a humidified
chamber. Sections were washed with PBS before sealing with
cover slips using Vectamount mounting medium.

Microscopy
Haematoxylin and Eosin and antibody stained sections are
scanned using Aperio Scan Scope CS2 system. Scanned
sections were analyzed using Aperio Image Scope viewer
software. Lesions were manually counted and graded based on
the recommendations of the Nikitin et al. and mouse models of
human cancer consortium [41].

Cell culture

Materials and Methods

Mouse embryonic fibroblasts (MEFs) were generated from
E13.5 embryos using standard procedures and cultured in
DMEM with 10% FBS and antibiotics [42]. Retroviral
transduction with pBABE-HrasV12 was as reported by Serrano
et al. [43] and viruses were packaged in Bosc-23 cells. Cells
infected with viruses encoding HrasV12 were selected in
4µg/ml puromycin for at least 3 days before sub-culturing for
further experiments. Senescent cells prepared by this method
were allowed to senescence for at least 10 days following
retroviral infection. Senescence associated β-galactosidase
(SA-β-Gal) staining was performed as described before [43].
Isolated foci were continuously sub-cultured in standard
medium with 4µg/ml puromycin and passaged every 3 days.

Ethics Statement
All animals were housed and handled as approved by the
UWO animal use subcommittee (protocol 2011-038) and
Canadian Council on Animal Care (CCAC) guidelines. All
tumor burdened animals were euthanized when they had
reached ethical endpoints.

Mouse strains
The generation of Rb1∆L/∆L mutant mice has been described
previously [26]. LSL-KrasG12D mice [18] were obtained from
the NCI mouse repository in a B6.129 background and
maintained as heterozygotes. Intercrosses with Rb1∆L mice
(also in B6.129 background), were performed to generate
compound mutant mice. Genotyping methods and PCR
primers were provided by the suppliers, or are as outlined by
Isaac, et al. [26].
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Soft agar colony forming assay
6 well dishes were coated with a bottom layer of 1.5ml 0.7%
low melting agarose in DMEM with 10% FBS and antibiotics.
3x104 cells were resuspended in 1.5ml of 0.35% low melting
agarose in DMEM with 10% FBS and antibiotics and added as
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the top layer to the 6 well plates. All genotypes were tested in
triplicate. Cells were allowed to grow in soft agar for 2 weeks
before counting the number of colonies formed.

3 times in PBS followed by mounting on slides with mounting
medium containing DAPI before analyzing by Confocal
microscopy.
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